EUVIMEDEUVIMED entdecken
Kohortenstudie

Coronavirus Disease 2019 Risk in Patients With Autoimmune Diseases Using Biologics or Small Molecules: A Population-Based Cohort Study

Eun Mi Song iD, Hyung-Mi An iD, Seong-Eun Kim, Ki-Nam Shim, Hye-Kyung Jung, Sung-Ae Jung, Chang Mo Moon iD

The Journal of Infectious Diseases · 2026

DOI: 10.1093/infdis/jiaf347 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Eun Mi Song und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea. Hauptthemen laut MEDLINE: Autoimmune Diseases, Biological Products, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Research Foundation of Korea, the Korea government (Ministry of Science and ICT), by the Ministry of Health and Welfare, Republic of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The role of biologics and small molecules in coronavirus disease 2019 (COVID-19) risk remains unclear. Therefore, we aimed to evaluate COVID-19 risk among patients with systemic autoimmune diseases treated with biologics or small molecules using the population-based cohort in Korea.

Methods

We compared COVID-19 risk in 46 639 patients treated with biologics or small molecules (biologics group) to a 1:2 propensity score–matched (PSM) group of 86 980 controls (nonbiologics group). We matched the groups based on age, sex, type of autoimmune disease, Charlson Comorbidity Index, concurrent medications, and pre-COVID-19 vaccine doses.

Results

After PSM, the biologics group exhibited a significantly higher COVID-19 risk (adjusted odds ratio [aOR], 1.20 [95% confidence interval {CI}, 1.08–1.34]) than the nonbiologics group. Subgroup analysis revealed a significant increase in COVID-19 risk in the biologics group that received suboptimal vaccines (aOR, 1.20 [95% CI, 1.08–1.34]). However, under optimal vaccine administration (3–4 doses), the risk of COVID-19 did not differ significantly between the biologics and nonbiologics groups (aOR, 1.22 [95% CI, .74–2.00]). Furthermore, COVID-19 risk significantly increased in patients with anti–tumor necrosis factor agents (aOR, 1.20 [95% CI, 1.05–1.36]), tofacitinib (aOR, 1.76 [95% CI, 1.15–2.71]), and abatacept (aOR, 1.98 [95% CI, 1.11–3.50]), compared with nonusers.

Conclusions

Among patients with systemic autoimmune diseases, the risk of COVID-19 was significantly higher in those taking biologics or small molecules than in those not taking biologics. When receiving suboptimal COVID-19 vaccination, the risk of COVID-19 significantly increased in the biologics compared to the nonbiologics group, but it was mitigated through optimal vaccinations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autoimmune DiseasesBiological ProductsCOVID-19HumansFemaleMaleMiddle AgedAgedRepublic of KoreaAdultSARS-CoV-2Cohort StudiesRisk FactorsCOVID-19 VaccinesPropensity Score

Stichwörter der Autor:innen

COVID-19autoimmune diseasebiologicssmall moleculesvaccine

Substanzen

Biological ProductsCOVID-19 Vaccines

Autor:innen und Institutionen

  • Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea.
  • Institute of Convergence Medicine, Ewha Womans University Mokdong Hospital, Seoul, Korea.
  • Department of Statistics and Data Science, Korea National Open University, Seoul, Republic of Korea.
  • Inflammation-Cancer Microenvironment Research Center, College of Medicine, Ewha Womans University, Seoul, Republic of Korea.
  • Department of Internal Medicine, Gibbeum Hospital, Seoul, Republic of Korea.

ORCID-Profile: Eun Mi Song, Hyung-Mi An, Chang Mo Moon

Förderung

  • National Research Foundation of Korea
  • the Korea government (Ministry of Science and ICT)
  • by the Ministry of Health and Welfare, Republic of Korea

Zitieren

APA

Song, E. M., An, H. M., Kim, S. E., Shim, K. N., Jung, H. K., Jung, S. A., & Moon, C. M. (2026). Coronavirus Disease 2019 Risk in Patients With Autoimmune Diseases Using Biologics or Small Molecules: A Population-Based Cohort Study. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf347

Vancouver

Song EM, An HM, Kim SE, Shim KN, Jung HK, Jung SA, et al. Coronavirus Disease 2019 Risk in Patients With Autoimmune Diseases Using Biologics or Small Molecules: A Population-Based Cohort Study. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiaf347

BibTeX
@article{Song2026,
  author = {Song, Eun Mi and An, Hyung-Mi and Kim, Seong-Eun and Shim, Ki-Nam and Jung, Hye-Kyung and Jung, Sung-Ae and Moon, Chang Mo},
  title = {Coronavirus Disease 2019 Risk in Patients With Autoimmune Diseases Using Biologics or Small Molecules: A Population-Based Cohort Study},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  doi = {10.1093/infdis/jiaf347}
}
Kostenlos starten →